Optimized treatment of HBeAg negative chronic hepatitis B guided by 'HBsAg at baseline and 24 week'

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017019

Enrollment

Unknown

Registered

2018-07-08

Start date

2018-08-01

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBeAg negative chronic hepatitis B

Interventions

ETV:take ETV

ETV+PEG-IFN:ETV and PEG-IFN

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The diagnosis of HBeAg negative CHB was consistent with the 2015 Chronic Hepatitis B Prevention Guide. After antiviral treatment of peg-interferon and nucleotide analogues, and maintenance the current nucleotide analogue treatment, HBsAg<1000IU/ml,HBeAg negative, HBV DNA<20IU/ml. Ultrasound B or Fibroscan did not indicate cirrhosis.

Exclusion criteria

Exclusion criteria: (1) Patients with HAV, HCV, HDV, HEV infection and autoimmune liver disease; (2) Pregnancy and lactation women and patients who are preparing to give birth in the near future; (3) Severe liver dysfunction or decompensatory cirrhosis; (4) History of serious heart disease, including unstable or uncontrolled heart disease within six months; (5) history of mental illness; (6) uncontrollable epilepsy; (7) alcoholic or drug addict; (8) Uncontrolled diabetes, hypertension, thyroid diseases, retinopathy, autoimmune diseases, etc.; (9) Neutrophils51umol/L.

Design outcomes

Primary

Measure	Time frame
HBsAg;	—

Countries

China

Contacts

Public ContactCao Zhenhuan

Beijing Youan Hospital Capital Medical University

caozhenhuanyu@aliyun.com+86 13810248004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026